Acurx Pharmaceuticals, engaged in pioneering Gram-positive targeted antibiotics through inhibition of DNA polymerase IIIC, has improved its financial performance with a 43.5% year-over-year net loss reduction in 2025. The company's lead candidate, ibezapolstat, is progressing in Phase 3 clinical trials targeting Clostridioides difficile infection (CDI) and recurrent CDI, with regulatory feedback including EMA pediatric guidance. Despite this clinical momentum, Acurx faces liquidity risks requiring additional capital amid ongoing operating losses and negative cash flows. Upcoming clinical data readouts and financing efforts will be pivotal for its runway and market prospects.